




Searching News Database: Daiichi Sankyo Group
HSMN NewsFeed - 12 Aug 2019
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
HSMN NewsFeed - 22 Feb 2019
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
HSMN NewsFeed - 14 Jul 2016
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
HSMN NewsFeed - 16 Oct 2015
Daiichi Sankyo, Inc. Reorganizes its U.S. Commercial Operations to Support Upcoming Specialty Pipeline
Daiichi Sankyo, Inc. Reorganizes its U.S. Commercial Operations to Support Upcoming Specialty Pipeline
HSMN NewsFeed - 19 Mar 2015
Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US
Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US
HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
HSMN NewsFeed - 17 Aug 2011
Daiichi Sankyo, Inc. Appoints Executive Vice President of Drug Development for the Americas
Daiichi Sankyo, Inc. Appoints Executive Vice President of Drug Development for the Americas
HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
HSMN NewsFeed - 15 Mar 2010
Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation
Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation